Table of Content

1. Preface
 1.1. Market Definition and Scope
 1.2. Market Segmentation
 1.3. Key Research Objectives
 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Market
4. Market Overview
 4.1. Introduction
  4.1.1. Definition
 4.2. Overview
 4.3. Market Dynamics
  4.3.1. Drivers
  4.3.2. Restraints
  4.3.3. Opportunities
 4.4. Global Market Analysis and Forecasts, 2024-2034
5. Market Outlook
 5.1. Disease Epidemiology
 5.2. Pipeline Analysis
 5.3. Recent Development
6. Global Market Analysis and Forecasts, by Drug Class
 6.1. Introduction & Definition
 6.2. Market Value Forecast by Drug Class, 2024-2034
  6.2.1. Corticosteroids
  6.2.2. PDE4 Inhibitors
  6.2.3. Biologics
  6.2.4. Skin Barrier Emollients
  6.2.5. CNI Immunosuppressants
  6.2.6. Others
 6.3. Market Attractiveness by Drug Class
7. Global Market Analysis and Forecasts, by Distribution Channel
 7.1. Introduction & Definition
 7.2. Market Value Forecast by Distribution Channel, 2024-2034
  7.2.1. Hospital Pharmacies
  7.2.2. Retail Pharmacies
  7.2.3. Online Pharmacies
 7.3. Market Attractiveness by Distribution Channel
8. Global Market Analysis and Forecasts, by Region
 8.1. Key Findings
 8.2. Market Value Forecast by Region
  8.2.1. North America
  8.2.2. Europe
  8.2.3. Asia Pacific
  8.2.4. Latin America
  8.2.5. Middle East & Africa
 8.3. Market Attractiveness by Country/Region
9. North America Market Analysis and Forecast
 9.1. Introduction
 9.2. Market Value Forecast by Drug Class, 2024-2034
  9.2.1. Corticosteroids
  9.2.2. PDE4 Inhibitors
  9.2.3. Biologics
  9.2.4. Skin Barrier Emollients
  9.2.5. CNI Immunosuppressants
  9.2.6. Others
 9.3. Market Value Forecast by Distribution Channel, 2024-2034
  9.3.1. Hospital Pharmacies
  9.3.2. Retail Pharmacies
  9.3.3. Online Pharmacies
 9.4. Market Value Forecast by Country, 2024-2034
  9.4.1. U.S.
  9.4.2. Canada
 9.5. Market Attractiveness Analysis
  9.5.1. By Drug Class
  9.5.2. By Distribution Channel
  9.5.3. By Country
10. Europe Market Analysis and Forecast
 10.1. Introduction
 10.2. Market Value Forecast by Drug Class, 2024-2034
  10.2.1. Corticosteroids
  10.2.2. PDE4 Inhibitors
  10.2.3. Biologics
  10.2.4. Skin Barrier Emollients
  10.2.5. CNI Immunosuppressants
  10.2.6. Others
 10.3. Market Value Forecast by Distribution Channel, 2024-2034
  10.3.1. Hospital Pharmacies
  10.3.2. Retail Pharmacies
  10.3.3. Online Pharmacies
 10.4. Market Value Forecast by Country/Sub-region, 2024-2034
  10.4.1. Germany
  10.4.2. U.K.
  10.4.3. France
  10.4.4. Spain
  10.4.5. Italy
  10.4.6. Rest of Europe
 10.5. Market Attractiveness Analysis
  10.5.1. By Drug Class
  10.5.2. By Distribution Channel
  10.5.3. By Country/Sub-region
11. Asia Pacific Market Analysis and Forecast
 11.1. Introduction
 11.2. Market Value Forecast by Drug Class, 2024-2034
  11.2.1. Corticosteroids
  11.2.2. PDE4 Inhibitors
  11.2.3. Biologics
  11.2.4. Skin Barrier Emollients
  11.2.5. CNI Immunosuppressants
  11.2.6. Others
 11.3. Market Value Forecast by Distribution Channel, 2024-2034
  11.3.1. Hospital Pharmacies
  11.3.2. Retail Pharmacies
  11.3.3. Online Pharmacies
 11.4. Market Value Forecast by Country/Sub-region, 2024-2034
  11.4.1. China
  11.4.2. Japan
  11.4.3. India
  11.4.4. Australia & New Zealand
  11.4.5. Rest of Asia Pacific
 11.5. Market Attractiveness Analysis
  11.5.1. By Drug Class
  11.5.2. By Distribution Channel
  11.5.3. By Country/Sub-region
12. Latin America Market Analysis and Forecast
 12.1. Introduction
 12.2. Market Value Forecast by Drug Class, 2024-2034
  12.2.1. Corticosteroids
  12.2.2. PDE4 Inhibitors
  12.2.3. Biologics
  12.2.4. Skin Barrier Emollients
  12.2.5. CNI Immunosuppressants
  12.2.6. Others
 12.3. Market Value Forecast by Distribution Channel, 2024-2034
  12.3.1. Hospital Pharmacies
  12.3.2. Retail Pharmacies
  12.3.3. Online Pharmacies
 12.4. Market Value Forecast by Country/Sub-region, 2024-2034
  12.4.1. Brazil
  12.4.2. Mexico
  12.4.3. Rest of Latin America
 12.5. Market Attractiveness Analysis
  12.5.1. By Drug Class
  12.5.2. By Distribution Channel
  12.5.3. By Country/Sub-region
13. Middle East & Africa Market Analysis and Forecast
 13.1. Introduction
 13.2. Market Value Forecast by Drug Class, 2024-2034
  13.2.1. Corticosteroids
  13.2.2. PDE4 Inhibitors
  13.2.3. Biologics
  13.2.4. Skin Barrier Emollients
  13.2.5. CNI Immunosuppressants
  13.2.6. Others
 13.3. Market Value Forecast by Distribution Channel, 2024-2034
  13.3.1. Hospital Pharmacies
  13.3.2. Retail Pharmacies
  13.3.3. Online Pharmacies
 13.4. Market Value Forecast by Country/Sub-region, 2024-2034
  13.4.1. GCC Countries
  13.4.2. South Africa
  13.4.3. Rest of Middle East & Africa
 13.5. Market Attractiveness Analysis
  13.5.1. By Drug Class
  13.5.2. By Distribution Channel
  13.5.3. By Country/Sub-region
14. Competitive Landscape
 14.1. Company Profiles
  14.1.1. Mylan N.V.
   14.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
   14.1.1.2. Product Portfolio
   14.1.1.3. SWOT Analysis
   14.1.1.4. Strategic Overview
   14.1.1.5. Financial Overview
  14.1.2. Pfizer, Inc.
   14.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
   14.1.2.2. Product Portfolio
   14.1.2.3. SWOT Analysis
   14.1.2.4. Strategic Overview
   14.1.2.5. Financial Overview
  14.1.3. LEO Pharma A/S
   14.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)
   14.1.3.2. Product Portfolio
   14.1.3.3. SWOT Analysis
   14.1.3.4. Strategic Overview
   14.1.3.5. Financial Overview
  14.1.4. Teva Pharmaceutical Industries Ltd
   14.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)
   14.1.4.2. Product Portfolio
   14.1.4.3. SWOT Analysis
   14.1.4.4. Strategic Overview
   14.1.4.5. Financial Overview
  14.1.5. Sanofi
   14.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)
   14.1.5.2. Product Portfolio
   14.1.5.3. SWOT Analysis
   14.1.5.4. Strategic Overview
   14.1.5.5. Financial Overview
  14.1.6. Novartis AG
   14.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)
   14.1.6.2. Product Portfolio
   14.1.6.3. SWOT Analysis
   14.1.6.4. Strategic Overview
   14.1.6.5. Financial Overview



List of Figures

Figure 01: Global Market Snapshot

Figure 02: Global Market Value (US$ Mn) and Distribution, by Region, 2024 and 2029

Figure 03: Global Market Value (US$ Mn) Forecast, 2024-2034

Figure 04: Global Market Value Share (%), by Drug Class (2024)

Figure 05: Global Market Value Share (%), by Distribution Channel (2024)

Figure 06: Global Market Value Share (%), by Region (2024)

Figure 07: Global Market Value Share Analysis, by Drug Class, 2024 and 2029

Figure 08: Global Market Attractiveness, by Drug Class, 2024-2029

Figure 09: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids, 2024-2034

Figure 10: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by PDE4 Inhibitors, 2024-2034

Figure 11: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Biologics, 2024-2034

Figure 12: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Skin Barrier Emollients, 2024-2034

Figure 13: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by CNI Immunosuppressants, 2024-2034

Figure 14: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2024-2034

Figure 15: Global Market Value Share (%), by Distribution Channel, 2024 and 2029

Figure 16: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2024-2034

Figure 17: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2024-2034

Figure 18: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2024-2034

Figure 19: Global Market Attractiveness, by Distribution Channel, 2024-2029

Figure 20: Global Market Value Share Analysis, by Region, 2024 and 2029

Figure 21: Global Market Attractiveness, by Region, 2024-2029

Figure 22: North America Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2024-2034

Figure 23: North America Market Value Share (%), by Country, 2024 and 2029

Figure 24: North America Market Attractiveness, by Country, 2024-2029

Figure 25: North America Market Value Share (%), by Drug Class, 2024 and 2029

Figure 26: North America Market Attractiveness, by Drug Class, 2024-2029

Figure 27: North America Market Value Share (%), by Distribution Channel, 2024 and 2029

Figure 28: North America Market Attractiveness, by Distribution Channel, 2024-2029

Figure 29: Europe Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2024-2034

Figure 30: Europe Market Value Share (%), by Country/Sub-region, 2024 and 2029

Figure 31: Europe Market Attractiveness, by Country/Sub-region, 2024-2029

Figure 32: Europe Market Value Share (%), by Drug Class, 2024 and 2029

Figure 33: Europe Market Attractiveness, by Drug Class, 2024-2029

Figure 34: Europe Market Value Share (%), by Distribution Channel, 2024 and 2029

Figure 35: Europe Market Attractiveness, by Distribution Channel, 2024-2029

Figure 36: Asia Pacific Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2024-2034

Figure 37: Asia Pacific Market Value Share (%), by Country/Sub-region, 2024 and 2029

Figure 38: Asia Pacific Market Attractiveness, by Country/Sub-region, 2024-2029

Figure 39: Asia Pacific Market Value Share (%), by Drug Class, 2024 and 2029

Figure 40: Asia Pacific Market Attractiveness, by Drug Class, 2024-2029

Figure 41: Asia Pacific Market Value Share (%), by Distribution Channel, 2024 and 2029

Figure 42: Asia Pacific Market Attractiveness, by Distribution Channel, 2024-2029

Figure 43: Latin America Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2020-2027

Figure 44: Latin America Market Value Share (%), by Country/Sub-region 2024 and 2029

Figure 45: Latin America Market Attractiveness, by Country/Sub-region, 2024-2029

Figure 46: Latin America Market Value Share (%), by Drug Class, 2024 and 2029

Figure 47: Latin America Market Attractiveness, by Drug Class, 2024-2029

Figure 48: Latin America Market Value Share (%), by Distribution Channel, 2024 and 2029

Figure 49: Latin America Market Attractiveness, by Distribution Channel, 2024-2029

Figure 50: Middle East & Africa Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2024-2034

Figure 51: Middle East & Africa Market Value Share (%), by Country/Sub-region 2024 and 2034

Figure 52: Middle East & Africa Market Attractiveness, by Country/Sub-region, 2024-2034

Figure 53: Middle East & Africa Market Value Share (%), by Drug Class, 2024 and 2034

Figure 54: Middle East & Africa Market Attractiveness, by Drug Class, 2024-2034

Figure 55: Middle East & Africa Market Value Share (%), by Distribution Channel, 2024 and 2034

Figure 56: Middle East & Africa Market Attractiveness, by Distribution Channel, 2024-2034

Figure 57: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2019-2023

Figure 58: Mylan N.V. R&D Expenses (US$ Mn), 2018-2020

Figure 59: Mylan N.V. Breakdown of Net Sales (%), by Region, 2020

Figure 60: Mylan N.V. Breakdown of Net Sales (%), by Business Segment, 2020

Figure 61: Pfizer, Inc. Breakdown of Net Sales, by Region, 2020

Figure 62: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015-2020

Figure 63: Pfizer, Inc. R&D Expenses (US$ Mn), 2018-2020

Figure 64: LEO Pharma A/S Breakdown of Net Sales, by Region (2018)

Figure 65: LEO Pharma A/S Breakdown of Net Sales, by Therapeutic Area (2018)

Figure 66: LEO Pharma A/S Revenue (US$ Mn) & Y-o-Y Growth (%), 2016-2020

Figure 67: LEO Pharma A/S R&D Expenses (US$ Mn), 2018-2020

Figure 68: Sanofi Revenue (US$ Bn), 2017-2020

Figure 69: Sanofi Regional Sales Breakdown (%), 2020

Figure 70: Novartis AG Breakdown of Net Sales, by Region, 2020

Figure 71: Novartis AG Breakdown of Net Sales, by Business Segment, 2020

Figure 72: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2017-2020

Figure 73: Novartis AG R&D Expenses (US$ Mn), 2018-2020

Figure 74: Teva Pharmaceutical Revenue (US$ Mn) & Y-o-Y Growth (%), 2016-2020

Figure 75: Teva Pharmaceutical R&D Expenses (US$ Mn), 2018-2020

Figure 76: Teva Pharmaceutical Breakdown of Net Sales, by Region, 2020

Figure 77: Teva Pharmaceutical Breakdown of Net Sales, (Overall Company Level), 2020

List of Tables

Table 01: Global Market Value (US$ Mn) Forecast, by Drug Class, 2024-2034

Table 02: Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2024-2034

Table 03: Global Market Value (US$ Mn) Forecast, by Region, 2024-2034

Table 04: North America Market Value (US$ Mn) Forecast, by Country, 2024-2034

Table 05: North America Value (US$ Mn) Forecast, by Drug Class, 2024-2034

Table 06: North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2024-2034

Table 07: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2024-2034

Table 08: Europe Value (US$ Mn) Forecast, by Drug Class, 2024-2034

Table 09: Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2024-2034

Table 10: Asia Pacific Market Value (US$ Mn) Forecast, by Country/Sub-region, 2024-2034

Table 11: Asia Pacific Value (US$ Mn) Forecast, by Drug Class, 2024-2034

Table 12: Asia Pacific Market Value (US$ Mn) Forecast, by Distribution Channel, 2024-2034

Table 13: Latin America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2024-2034

Table 14: Latin America Value (US$ Mn) Forecast, by Drug Class, 2024-2034

Table 15: Latin America Market Value (US$ Mn) Forecast, by Distribution Channel, 2024-2034

Table 16: Middle East & Africa Market Value (US$ Mn) Forecast, by Country/Sub-region, 2024-2034

Table 17: Middle East & Africa Value (US$ Mn) Forecast, by Drug Class, 2024-2034

Table 18: Middle East & Africa Market Value (US$ Mn) Forecast, by Distribution Channel, 2024-2034